Literature DB >> 9845082

The lifetime of hypoxic human tumor cells.

R E Durand1, E Sham.   

Abstract

PURPOSE: For hypoxic and anoxic cells in solid tumors to be a therapeutic problem, they must live long enough to be therapeutically relevant, or else be rapidly recruited into the proliferating compartment during therapy. We have, therefore, estimated lifetime and recruitment rate of hypoxic human tumor cells in multicell spheroids in vitro, or in xenografted tumors in SCID mice.
MATERIALS AND METHODS: Cell turnover was followed by flow cytometry techniques, using antibodies directed at incorporated halogenated pyrimidines. The disappearance of labeled cells was quantified, and verified to be cell loss rather than label dilution. Repopulation was studied in SiHa tumor xenografts during twice-daily 2.5-Gy radiation exposures.
RESULTS: The longevity of hypoxic human tumor cells in spheroids or xenografts exceeded that of rodent cell lines, and cell turnover was slower in xenografts than under static growth as spheroids. Human tumor cells remained viable in the hypoxic regions of xenografts for 4-10 days, compared to 3-5 days in spheroids, and 1-3 days for most rodent cells in spheroids. Repopulation was observed within the first few radiation treatments for the SiHa xenografts and, with accumulated doses of more than 10 Gy, virtually all recovered cells had progressed through at least one S-phase.
CONCLUSION: Our results suggest an important difference in the ability of human vs. rodent tumor cells to withstand hypoxia, and raise questions concerning the increased longevity seen in vivo relative to the steady-state spheroid system.

Entities:  

Mesh:

Year:  1998        PMID: 9845082     DOI: 10.1016/s0360-3016(98)00305-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

2.  Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Authors:  Xinjian Mao; Sarah McManaway; Jagdish K Jaiswal; Cho R Hong; William R Wilson; Kevin O Hicks
Journal:  Cancer Biol Ther       Date:  2019-05-26       Impact factor: 4.742

3.  Response to multiple radiation doses of fibroblasts over-expressing dominant negative Ku70.

Authors:  Muneyasu Urano; Yunhong Huang; Fuqiu He; Akiko Minami; C Clifton Ling; Gloria C Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

4.  Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease.

Authors:  Sylvia Plevritis; Alexander R A Anderson; Jill Gallaher; Aravind Babu
Journal:  Cancer Res       Date:  2014-01-09       Impact factor: 12.701

5.  Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts.

Authors:  Brennan J Wadsworth; Che-Min Lee; Kevin L Bennewith
Journal:  Br J Cancer       Date:  2022-01-14       Impact factor: 9.075

6.  The HYP-RT hypoxic tumour radiotherapy algorithm and accelerated repopulation dose per fraction study.

Authors:  W M Harriss-Phillips; E Bezak; E Yeoh
Journal:  Comput Math Methods Med       Date:  2012-06-19       Impact factor: 2.238

Review 7.  Pathophysiological Basis for the Formation of the Tumor Microenvironment.

Authors:  Michael R Horsman; Peter Vaupel
Journal:  Front Oncol       Date:  2016-04-12       Impact factor: 6.244

8.  In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model.

Authors:  Eleni Kolokotroni; Dimitra Dionysiou; Christian Veith; Yoo-Jin Kim; Jörg Sabczynski; Astrid Franz; Aleksandar Grgic; Jan Palm; Rainer M Bohle; Georgios Stamatakos
Journal:  PLoS Comput Biol       Date:  2016-09-22       Impact factor: 4.475

9.  Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma.

Authors:  D Shneor; R Folberg; J Pe'er; A Honigman; S Frenkel
Journal:  Cancer Gene Ther       Date:  2016-12-09       Impact factor: 5.987

10.  Studying the regression profiles of cervical tumours during radiotherapy treatment using a patient-specific multiscale model.

Authors:  Christos A Kyroudis; Dimitra D Dionysiou; Eleni A Kolokotroni; Georgios S Stamatakos
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.